![\"\"](\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2019\/10\/IDWeek-2019-logo-300x92.png\"){kind=logo}
<\/h2>\n<\/h2>\nMark Mascolini, natap.org<\/span><\/strong><\/p>\n Prevalence of nonalcoholic fatty liver disease\u00a0(NAFLD)\u00a0lay above 50% in a two-thirds black HIV group in Newark, NJ, higher than the 43% prevalence reported in a largely white HIV group in Palermo, Italy. [1] <\/span><\/strong><\/p>\n The US group had spent an average five more years on antiretroviral therapy (ART)\u00a0than the Palermo group, and a higher proportion in the US\u00a0cohort\u00a0had diabetes. Prevalence of nonalcoholic steatohepatitis (NASH) was also higher\u00a0in the US group.\u00a0<\/span><\/p>\n A review of recent literature\u00a0noted\u00a0increasing reports of NAFLD and NASH in people with HIV infection [2].\u00a0A Netherlands group\u00a0proposed that insulin resistance, mitochondrial dysfunction, and dyslipidemia\u00a0drive\u00a0NAFLD pathogenesis and progression to NASH\u00a0in people with HIV\u00a0[3].\u00a0But prevalence and risk factors for these conditions remain poorly understood, as does the potential impact of ART.\u00a0<\/span><\/p>\n To learn more about NAFLD and NASH\u00a0in ART-treated people, clinicians at Saint Michael’s Medical Center in Newark prospectively gathered data on HIV positive people undergoing transient elastography\u00a0(TE)\u00a0at their center from November 2017 to September 2018. They compared their findings with a recent report on NAFLD and NASH in HIV-monoinfected\u00a0patients at the University Hospital of\u00a0Palermo\u00a0[4]. The Newark team defined NAFLD and fibrosis severity\u00a0by the same measures used in Palermo, Controlled Attenuation Parameter (CAP)\u00a0above 248 dB\/m and TE above\u00a07.1\u00a0Kpa.\u00a0<\/span><\/p>\n The Newark cohort included 624 consecutive patients with HIV, who did not differ significantly from the Palermo group in age\u00a0or\u00a0sex. NAFLD prevalence was high in both groups, but higher in Newark (51.6%) than in Palermo (42.7%). Among people with NAFLD,\u00a0NASH\u00a0prevalence was also higher in Newark (31%) than Palermo (23%).\u00a0<\/span><\/p>\n The Newark and Palermo patient clusters differed in race (68% black in Newark, 87% white in Palermo), diabetes prevalence (20% in Newark, 6% in Palermo, although body mass index did not differ significantly between groups), and longer time on ART\u00a0in Newark (average 5 years). The Newark team also noted trends in a lower percentage of patients with a viral load below 20 copies, a lower average CD4 count, a higher percentage taking integrase inhibitors, and a higher\u00a0prevalence\u00a0of hypertension in the Newark patients.\u00a0<\/span><\/p>\n The Newark investigators concluded that the prevalence of NAFLD is alarmingly high in people with HIV. Gaining a better understanding of NAFLD in HIV patients is urgent, they stressed, \u201cto prevent the potentially severe consequences of NASH\u201d. Because their study suggested longer antiretroviral duration may favour development of NAFLD, the Newark team urged closer monitoring of liver health as soon as ART begins.<\/span><\/p>\n References<\/span><\/p>\n Mark Mascolini, natap.org Prevalence of nonalcoholic fatty liver disease\u00a0(NAFLD)\u00a0lay above 50% in a two-thirds black HIV group in Newark, NJ, higher than the 43% prevalence reported in a largely white HIV group in Palermo, Italy. [1] The US group had …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,27],"tags":[274],"class_list":["post-36716","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-weight-diabetes-metabolic-complications","tag-idweek-2019"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/36716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=36716"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/36716\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=36716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=36716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=36716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\nhttp:\/\/natap.org\/2019\/IDWeek\/IDWeek_09.htm<\/a> (natap report)<\/span><\/li>\n
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6374241\/<\/a>\u00a0<\/span><\/li>\n